Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDMonte Rosa Therapeutics Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 3 | -$0.69 | -$0.23 | -$0.48 |
| Q2 2026 | 1 | -$0.95 | -$0.17 | -$0.48 |
| Q3 2026 | 1 | -$0.92 | -$0.17 | -$0.46 |
| Q4 2026 | 1 | -$0.96 | -$0.17 | -$0.48 |
Monte Rosa Therapeutics Inc Earnings Date And Information
Monte Rosa Therapeutics Inc last posted its earnings results on Thursday, November 6th, 2025. The company reported $-0.33 earnings per share for the quarter, topping analysts' consensus estimates of $-0.39 by $0.06. The company had revenue of 12.77 M for the quarter and had revenue of 75.62 M for the year. Monte Rosa Therapeutics Inc has generated $-1 earnings per share over the last year ($-0.98 diluted earnings per share) and currently has a price-to-earnings ratio of 71.91. Monte Rosa Therapeutics Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Monte Rosa Therapeutics Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2025 | Q3 2025 | -$0.39 | -$0.33 | 0.06 | $7.37 M | $12.77 M |
| 08/07/2025 | Q2 2025 | -$0.31 | -$0.15 | 0.16 | $7.38 M | $23.19 M |
| 05/08/2025 | Q1 2025 | -$0.24 | $0.57 | 0.81 | N/A | $84.93 M |
| 03/20/2025 | Q4 2024 | -$0.37 | $0.22 | 0.59 | N/A | $60.65 M |
| 11/07/2024 | Q3 2024 | -$0.45 | -$0.29 | 0.16 | $2.64 M | $9.22 M |
| 08/08/2024 | Q2 2024 | -$0.50 | -$0.43 | 0.07 | $1.35 M | $4.70 M |
| 05/09/2024 | Q1 2024 | -$0.56 | -$0.53 | 0.03 | N/A | $1.06 M |
| 03/14/2024 | Q4 2023 | -$0.57 | -$0.58 | -0.01 | N/A | $0 |
| 11/09/2023 | Q3 2023 | -$0.75 | -$0.70 | 0.05 | N/A | $0 |
| 08/10/2023 | Q2 2023 | -$0.72 | -$0.71 | 0.01 | N/A | $0 |
| 05/11/2023 | Q1 2023 | -$0.70 | -$0.60 | 0.1 | N/A | $0 |
| 03/16/2023 | Q4 2022 | -$0.64 | -$0.59 | 0.05 | N/A | $0 |
| 11/10/2022 | Q3 2022 | -$0.61 | -$0.56 | 0.05 | N/A | $0 |
| 08/11/2022 | Q2 2022 | -$0.54 | -$0.55 | -0.01 | N/A | $0 |
| 05/11/2022 | Q1 2022 | -$0.53 | -$0.51 | 0.02 | N/A | $0 |
| 03/29/2022 | Q4 2021 | -$0.50 | -$0.51 | -0.01 | N/A | $0 |
| 11/10/2021 | Q3 2021 | -$0.46 | -$0.43 | 0.03 | N/A | $0 |
| 08/12/2021 | Q2 2021 | -$0.40 | -$3.63 | -3.23 | N/A | $0 |
| 03/30/2021 | Q1 2021 | N/A | -$0.29 | N/A | N/A | $0 |
| 12/30/2020 | Q4 2020 | N/A | -$0.90 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Monte Rosa Therapeutics Inc Earnings: FAQ's
In the previous quarter, Monte Rosa Therapeutics Inc (:GLUE) reported $-0.33 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.39 by $0.06.
The conference call for Monte Rosa Therapeutics Inc's latest earnings report can be listened to online.
The conference call transcript for Monte Rosa Therapeutics Inc's latest earnings report can be read online.
Monte Rosa Therapeutics Inc (:GLUE) has a recorded annual revenue of $75.62 M.
Monte Rosa Therapeutics Inc (:GLUE) has a recorded net income of $-72,700,000.Monte Rosa Therapeutics Inc has generated $-0.98 earnings per share over the last four quarters.
Monte Rosa Therapeutics Inc (:GLUE) has a price-to-earnings ratio of 71.91 and price/earnings-to-growth ratio is -6.29.